Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association.
Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association.
复制标题
日本 II/III 期尿路上皮癌治疗方式的多样性：日本泌尿外科协会多机构国家数据库的子分析。
DOI：
10.1093/jjco/hyw005
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Hara T
中科院分区：
文献类型：
--
作者：
Koie T;Ohyama C;Fujimoto H;Nishiyama H;Miyazaki J;Hinotsu S;Kikuchi E;Sakura M;Inokuchi J;Hara T
目的 调查日本 II/III 期尿路上皮癌患者的治疗方式。方法使用日本泌尿外科协会的多机构国家数据库，包括 348 个日本机构，其中 2008 年和 2011 年分别登记了 3707 例肌层浸润性膀胱癌患者和 1538 例上尿路尿路上皮癌患者。主要治疗分为单纯手术、手术化疗、手术放疗、单纯放疗、单纯化疗、放化疗联合观察。使用Kaplan-Meier法检查总体生存率和癌症特异性生存率，并使用时序检验分析亚组生存率。结果在II/III期膀胱癌患者中，49.7%接受根治性手术治疗，22.3%仅接受观察。共有97.2%的II/III期上尿路尿路上皮癌患者接受了根治性手术。共有30.4%的II/III期膀胱癌患者接受了化疗。大多数患者接受以顺铂为主的方案，但化疗方案种类丰富，多达13种方案。上尿路尿路上皮癌患者的化疗方案也多种多样，多达八种方案。总体生存率和癌症特异性生存率根据临床分期进行统计学显着分层。与临床T2期诊断的上尿路尿路上皮癌患者相比，临床T3期诊断的上尿路尿路上皮癌患者的预后明显较差。结论本研究证明了日本II/III期尿路上皮癌患者使用的多种治疗方法。这些实体的治疗标准化可能是必要的。
ObjectiveWe aimed to survey treatment modalities for the patients with Stage II/III urothelial cancer in Japan.MethodsWe used the multi-institutional national database of the Japanese Urological Association from 348 Japanese institutions, in which a total of 3707 patients with muscle-invasive bladder cancer and 1538 with upper urinary tract urothelial carcinoma were registered in 2008 and 2011, respectively. Primary treatment was classified as surgery alone, surgery with chemotherapy, surgery with radiation, radiation alone, chemotherapy alone, combination of radiation and chemotherapy and observation. Overall and cancer-specific survivals were examined using the Kaplan–Meier method, and survival in the subgroups was analyzed using the log-rank test.ResultsIn Stage II/III bladder cancer patients, 49.7% of those were treated with radical operation and 22.3% received observation only. A total 97.2% of Stage II/III upper urinary tract urothelial carcinoma patients treated with radical surgery. A total 30.4% of Stage II/III bladder cancer patients received chemotherapy. Majority of the patients received cisplatin-based regimen, however, regimens of chemotherapy was rich in variety up to 13 regimens. Chemotherapy regimens for the patients with upper urinary tract urothelial carcinoma were also various up to eight regimens. Overall and cancer-specific survivals were statistically significantly stratified according to the clinical stage. The upper urinary tract urothelial carcinoma patients diagnosed with clinical stage T3 had significantly poor prognosis compared with those diagnosed with clinical stage T2.ConclusionsThis study demonstrated the variety of treatments used for Japanese patients with Stage II/III urothelial cancer. Treatment standardization for these entities may be necessary.